The estimated Net Worth of Stanford L Peng is at least $23.3 Million dollars as of 8 May 2024. Stanford Peng owns over 271,792 units of Alpine Immune Sciences Inc stock worth over $22,360,270 and over the last 7 years he sold ALPN stock worth over $0. In addition, he makes $970,591 as President and Head of Research and Development at Alpine Immune Sciences Inc.
Stanford has made over 1 trades of the Alpine Immune Sciences Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 271,792 units of ALPN stock worth $668,608 on 8 May 2024.
The largest trade he's ever made was exercising 271,792 units of Alpine Immune Sciences Inc stock on 8 May 2024 worth over $668,608. On average, Stanford trades about 19,414 units every 0 days since 2017. As of 8 May 2024 he still owns at least 344,163 units of Alpine Immune Sciences Inc stock.
You can see the complete history of Stanford Peng stock trades at the bottom of the page.
Dr. Stanford L. Peng M.D., Ph.D. serves as President and Head of Research and Development of the Company. He was serves as Executive Vice President - Research and Development, Chief Medical Officer of the company. He has as served as our executive vice president of research and development and chief medical officer since the completion of the Merger in July 2017 and previously served as Private Alpine’s chief medical officer From September 2016 to February 2017 and as Private Alpine’s executive vice president of research and development and chief medical officer since February 2017. Prior to joining Private Alpine, Dr. Peng was chief medical officer and head of clinical development at Stemcentrx, providing strategic oversight of the company’s clinical and translational programs from 2015 to 2016. Previously, Dr. Peng was executive medical director at Seattle Genetics where he developed multiple programs for antibody-drug conjugates from 2014 to 2015. Earlier in his career, he directed translational research and auto-immune related clinical trials as head of the Rheumatology Clinical Research Unit at the Benaroya Research Institute from 2009 to 2014 and served as senior director, clinical research and exploratory development at Roche from 2005 to 2008. Between 2009 and 2014, Dr. Peng also served as member physician at Virginia Mason Medical Center. Dr. Peng served as an assistant professor at the Washington University School of Medicine from 2002 to 2005. From 2008 to 2009, Dr. Peng served as senior director at ARYx Therapeutics, Inc. (Nasdaq: ARYX). Dr. Peng received an M.D. and Ph.D. in biology from the Yale University School of Medicine and a B.A. in music and B.S. in biological sciences from Stanford University.
As the President and Head of Research and Development of Alpine Immune Sciences Inc, the total compensation of Stanford Peng at Alpine Immune Sciences Inc is $970,591. There are 1 executives at Alpine Immune Sciences Inc getting paid more, with Mitchell Gold having the highest compensation of $1,555,930.
Stanford Peng is 49, he's been the President and Head of Research and Development of Alpine Immune Sciences Inc since 2019. There are 10 older and 5 younger executives at Alpine Immune Sciences Inc. The oldest executive at Alpine Immune Sciences Inc is Dr. Jan L. Hillson Ph.D., M.D., 67, who is the Sr. VP of Clinical Devel..
Stanford's mailing address filed with the SEC is C/O ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE, WA, 98102.
Over the last 7 years, insiders at Alpine Immune Sciences Inc have traded over $91,012,519 worth of Alpine Immune Sciences Inc stock and bought 8,061,426 units worth $69,477,679 . The most active insiders traders include Peter A. Thompson, Advisors Llc Orbi Med Capit..., and James N Topper. On average, Alpine Immune Sciences Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,201,670. The most recent stock trade was executed by Stanford L Peng on 8 May 2024, trading 271,792 units of ALPN stock currently worth $668,608.
founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.
Alpine Immune Sciences Inc executives and other stock owners filed with the SEC include: